Annovis Bio, Inc. (ANVS) News
Track canonical SquawkNews coverage tagged to ANVS, Annovis Bio, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 2 indexed stories across 2 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Annovis (ANVS) reports second-quarter 2026 results and corporate updates
Annovis (ANVS) issues corporate updates alongside its second-quarter 2026 financial results, according to the provided headline text.
EARNINGS | Aug 14, 2026, 12:00 PM UTC
H
Annovis Bio Announces Full Enrollment Of Its Phase 3 Trial Of Buntanetap In Patients With Early Alzheimer’s Disease; The Trial Enrolled 850
Annovis Bio, Inc. (NYSE: ANVS ) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s dis
EARNINGS | Jul 07, 2026, 11:19 AM UTC